Last updated: 2026-10-19 20:50:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
IRulya Therapeutics Inc. (IRLA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $33.65, with a market capitalization of $32.58M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.13 to $34.93. This page covers its latest market performance, valuation, price trends and company information.
$32.58M | |
$31.17 | |
$34.93 | |
$25.13 | |
$32.03 | |
41.33K | |
41.75K | |
-- | |
$34.93 | |
$25.13 | |
-- | |
-- |
IRulya Therapeutics Inc. (IRLA) is trading at $33.70 in after-hours trading as of 2026-10-19 20:49:00, up 5.22% ($1.67) from the regular-session close of $32.03.
After-hours trading shows how investors are pricing IRLA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, IRulya Therapeutics Inc. (IRLA) moved from $32.40 to $33.65, representing a gain of 3.85% ($1.25).
The stock traded between $25.13 and $34.93 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 41.75 thousand shares, -- versus the previous seven-day period, indicating -- trading activity.
Position in Range: 86.9%
IRLA is currently trading at $33.65, placing it 86.9% of the way from its 52-week low of $25.13 to its 52-week high of $34.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 38 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of IRulya Therapeutics Inc. (IRLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.